
chlorambucil-prednisolone therapy 
disseminated breast carcinoma 
7 1/2-year period, 71 patients 
disseminated breast cancer treated 
combined alkylating-agent-cortico- 
steroid therapy.  chlorambucil pred- 
nisolone drugs choice.  
agents, administered orally, produced 
serious disagreeable toxic effects.  twen- 
ty-four patients (33.8%) objective 
regression six months' duration long- 
er; average survival time therapy 
23.9 months.  results statistically 
similar obtained sex-steroid 
endocrine-ablation therapy, presum- 
ably three modalities 
similar mechanism action, ie. suppres- 
sion and/or eradication endogenous 
estrogen. 
